Apigenin (Chamomile Extract).

Apigenin binds the benzodiazepine site and raises the receptor's response to whatever GABA is present. It modulates rather than activates, so it needs GABAergic tone to act on.

Apigenin works on the inhibitory side at GABA-A while theanine acts on the glutamatergic side and raises alpha-band cortical activity. The two reach the same calm state from opposite directions.

Melatonin signals through MT1 and MT2 receptors on the circadian timing side, and apigenin acts allosterically at GABA-A on the arousal side. Neither competes for the other's binding site, which is why they are formulated together in evening blends.

Magnesium is a positive modulator at GABA-A and blocks the NMDA channel in a voltage-dependent way. It sets the background on the same receptors apigenin modulates allosterically.

Passionflower carries its own flavone set acting at GABA-A, and the two botanicals have been combined in calming preparations for generations. The overlap is at the same receptor, so the combined effect is not simply additive.

Luteolin is apigenin with one extra hydroxyl on the B ring, and the two occur together in chamomile and related composites. They share the flavone conjugation route, so co-dosing means competition for the same glucuronidation and sulfation capacity.

Both flavonoids are cleared mainly by UGT and SULT enzymes in the gut wall and liver. Given together they compete for that capacity, which can raise the free fraction of each above what either reaches alone.

Piperine slows intestinal glucuronidation and efflux, the two steps that limit how much of an ingested flavone reaches circulation. Apigenin is heavily conjugated on first pass, so it is a typical beneficiary.

Ascorbate reduces the flavonoid phenoxyl radical formed when a flavone quenches an oxidant, returning the flavone to its active form. The pairing extends the working life of both in an aqueous phase.

The catechol and carbonyl groups on flavones bind ferric iron and hold it in a form the intestinal transporter cannot take up. Taking a flavonoid-rich extract with an iron dose lowers how much of that iron is absorbed, so they are separated by a couple of hours.

Chamomile carries most of its apigenin as apigenin-7-O-glucoside and related glycosides rather than free aglycone. Gut bacteria supply the beta-glucosidase activity that cleaves the sugar, and the aglycone is what crosses the intestinal wall. Colonic flora composition therefore sets how much free apigenin appears from a given extract. The relationship is mechanistic; it has not been quantified in a controlled human co-supplementation study.

Inulin is fermented by bifidobacteria and lactobacilli, the same groups that carry beta-glucosidase activity against plant glycosides. Shifting that population is the plausible route by which a prebiotic would change apigenin release from chamomile. This is a mechanistic chain rather than a measured co-supplementation result, and no dose relationship has been established.

Free apigenin is a flat, poorly water-soluble flavone with low dissolution in gut fluid. Phospholipid dispersions and phytosome-type complexes are the standard formulation answer for that class of molecule, keeping the aglycone in a dispersed state through the small intestine. The pairing is formulation chemistry, not a claimed clinical effect.

Phosphatidylcholine complexes are used across the flavonoid class to raise apparent solubility of the aglycone. The phospholipid head group associates with the flavone and the resulting complex disperses more readily in intestinal fluid. Read it as a delivery-chemistry pairing; the size of any absorption change for apigenin specifically has not been fixed by trial.

Apigenin aglycone partitions into lipid rather than water. Medium-chain triglycerides give it a carrier phase and prompt bile release, which is the general route by which lipophilic plant compounds reach the enterocyte. No human pharmacokinetic study has measured this pairing for apigenin.

Apigenin is cleared largely as glucuronide and sulfate conjugates formed in the gut wall and liver. Curcumin is handled by the same UGT and SULT families and inhibits several of them. Taken together at high doses, each can slow the other's conjugation, which raises free concentrations without any added benefit being demonstrated. Worth flagging as a handling interaction rather than a synergy.

Resveratrol is a strong sulfotransferase substrate and inhibitor, and apigenin is sulfated by overlapping isoforms. Co-exposure shifts the conjugation load between them. The direction is predictable from enzyme chemistry; the magnitude in people has not been measured.

Naringenin and apigenin appear together in the literature as flavonoids competing for the same intestinal glucuronidation and efflux steps. Co-ingestion redistributes that capacity rather than adding independent effects. This is a metabolic overlap noted in flavonoid pharmacology, not a demonstrated joint outcome.

Propolis contains chrysin, galangin and related flavones structurally close to apigenin, and the two appear together in botanical preparations. Total flavone exposure adds up when both are taken. Nothing has tested the combination as a combination.

Oxidised flavone intermediates are conjugated by glutathione S-transferase, which is part of normal flavonoid disposal. Glutathione status therefore shapes how apigenin oxidation products are handled. This is established conjugation chemistry, measured as a marker rather than a clinical endpoint.

Tocopherols act inside the membrane lipid phase while flavones sit mainly at the membrane surface and in aqueous compartments. The two occupy different positions in the same antioxidant network, which is why they are often formulated together. Support for the pairing is mechanistic, with markers rather than outcomes behind it.

Tryptophan feeds serotonin and then melatonin synthesis, while apigenin binds at the benzodiazepine site of the GABA-A receptor. Two separate routes into the same normal wind-down process is the rationale for pairing them in evening formulas. No trial has run the combination, so the confidence stays low.

Chamomile and lemon balm have been combined in evening teas for a very long time, and lemon balm's rosmarinic acid affects GABA transaminase. The mechanistic stories run in parallel. What exists is tradition plus separate mechanism work, not a combination trial.

Both botanicals interact with GABA-A signalling by different routes, so calming effects can stack. That is the reason to flag the pairing rather than to promote it: additive sedation matters for anyone already taking something that slows the central nervous system. The interaction is inferred from each botanical's own mechanism work.

Magnolia lignans are positive modulators at GABA-A sites distinct from the benzodiazepine site apigenin occupies. Combined use raises total modulation of the same receptor complex. Flagged for the additive sedation, with no combination study behind it.